Cytokinetics (CYTK) Total Liabilities (2016 - 2025)
Historic Total Liabilities for Cytokinetics (CYTK) over the last 16 years, with Q3 2024 value amounting to $1.4 billion.
- Cytokinetics' Total Liabilities rose 2293.98% to $1.4 billion in Q3 2024 from the same period last year, while for Sep 2024 it was $1.4 billion, marking a year-over-year increase of 2293.98%. This contributed to the annual value of $1.2 billion for FY2023, which is 783.52% up from last year.
- According to the latest figures from Q3 2024, Cytokinetics' Total Liabilities is $1.4 billion, which was up 2293.98% from $1.4 billion recorded in Q2 2024.
- In the past 5 years, Cytokinetics' Total Liabilities registered a high of $1.4 billion during Q3 2024, and its lowest value of $302.3 million during Q1 2020.
- Moreover, its 5-year median value for Total Liabilities was $740.0 million (2022), whereas its average is $836.7 million.
- Per our database at Business Quant, Cytokinetics' Total Liabilities soared by 8874.71% in 2022 and then surged by 763.36% in 2024.
- Cytokinetics' Total Liabilities (Quarter) stood at $420.4 million in 2020, then soared by 42.11% to $597.5 million in 2021, then skyrocketed by 87.91% to $1.1 billion in 2022, then rose by 7.84% to $1.2 billion in 2023, then grew by 19.77% to $1.4 billion in 2024.
- Its last three reported values are $1.4 billion in Q3 2024, $1.4 billion for Q2 2024, and $1.2 billion during Q1 2024.